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There is a column shift in Table 1, WT row i.e. Total No. of
isolates were shifted to LPA; No. Of isolates to Total no. of
isolates; AMK MICs are shifted to No. of isolates.
Unfortunately, we have realized that there are typograph-
ical errors in the final published version of the manuscript.
We have highlighted the corrected sentences.
(a) In Materials and Methods under section of Quantitative
DST:
Six concentrations of KAN and seven concentrations
of AMK and CAP were used to establish the MICs for the
M. tuberculosis isolates included in this study.
This should be corrected to
Six concentrations of KAN and AMK; seven concentrations
of CAP were used to establish the MICs for theM. Tuberculosis
isolates included in this study.
(b) In Materials and Methods under section of setting and
ethical approval:Written consent was waived for all participants as the
study was carried out on 90 archived isolates for which
pyrosequencing, GenoTypeMTBDRslassay (version 1) and
MGIT960 DST (utilizing WHO-approved critical concentra-
tions) were previously performed.
This should be changed to
A written consent was waived for all participants as the
study was carried out on 90 archived isolates, for which Gen-
oTypeMTBDRslassay (version 1) and MGIT960 DST (utilizing
WHO-approved critical concentrations) had been previously
performed. Pyrosequencing was performed on 20 representa-
tive isolates.
(c) In Results:
Titled ‘‘Table 1: Mutations found within Mycobacterium
tuberculosis clinical isolates and their associated minimum
inhibitory concentrations against the second-line injectables”
in the column titled CAP, in the row G-10A,
0.125 should be corrected to 1.25
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Phenotypic DST and MIC results:
Sixty phenotypically XDR-TB strains were included in this
study. Eleven (found to have eis promoter mutations) were
resistant to KAN at the critical concentration, but sensitive
to AMK and CAP. Forty-eight isolates (determined to have
the rrs A1401G mutation) were found to be resistant to KAN,
AMK, and CAP. One isolate (with WT sequences for both the
rrs and eis promoter) was also resistant to KAN, AMK, and
CAP at the critical concentration. Thirty isolates were pan
susceptible to all drugs tested. The MICs of AMK, KAN, and
CAP for all isolates are shown in Table 1.
This should be changed to
Phenotypic results:
Of the eleven found to have eis promoter mutations eight
were resistant to KAN at the critical concentration, but sen-
sitive to AMK and CAP whereas, three were sensitive to
AMK, KAN and CAP at critical concentration. Forty-eight iso-
lates (determined to have the rrs A1401G mutation) were
found to be resistant to KAN, AMK, and CAP. One isolate
(with WT sequences for both the rrs and eis promoter)
was also resistant to KAN, AMK, and CAP at the critical con-
centration. Thirty isolates were pan susceptible to all drugs
tested.
Genotypic results:
The agreement between the GenoType MTBDRsl assay
results (based solely upon the presence of resistance-associ-
ated rrsmutations) and the phenotypic DST was 97% for
AMK, 96% for KAN, and 86% for CAPTable 1 – Mutations found within Mycobacterium tuberculosis cli
line injectables.
Mutation LPAa Total No. of Isolates
rrs
A1401G MUT1 48
eis
G-10C Wild-type 3
G-10A Wild-type 3
C-12T Wild-type 2
C-14T Wild-type 3
WT
WTb 1
WT 30
Note: AMK = amikacin; CAP = capreomycin; KAN = kanamycin; WT = wild
a Line probe assay.
b One isolate, characterized as WT, but resistant to AMK, KAN, and CAP
regions not assessed by MTBDRsl or pyrosequencing.Should be changed to
The agreement between the GenoType MTBDRsl assay
results (based solely upon the presence of resistance-associ-
ated rrs mutations) and the phenotypic DST was 98.8% for
AMK and CAP; 90% for KAN.
(e) At all instances of 0.625 for KAN and CAP; 0.25 for AMK
the 6 symbol needs to be included before the actual number,
that is, 0.625 needs to be changed to 60.625 and 0.25 should
be changed to 60.25.
Please also include this symbol 6 in Table 1 (see below)
(f) In Results; Correlation of KAN MICs with Resistance-
Associated Mutations
Should be changed to
Correlation of AMK, KAN and CAP MICs with Resistance-
Associated Mutations.
Under the same section Correlation of KAN MICs with
Resistance-Associated Mutations
Isolates harboring the rrs A1401G mutation had AMK, KAN
and CAP MICs of >40, >20, and 5–15 mg/L, respectively,
whereas isolates with eis promoter mutations were found to
have AMK, KAN and CAP MICs ranging from 0.25–1.0, 5.0–10,
and 0.625–2.5 mg/L, respectively (Table 1).
Should be changed to
Isolates harboring the rrsA1401Gmutation had AMK, KAN
and CAP MICs of >40, >20, and 5–15 mg/L, respectively,
whereas isolates with eis promoter mutations were found to
have AMK, KAN and CAP MICs ranging from 60.25–1.0 mg/L,
60.625–10 mg/L, and 60.625–2.5 mg/L, respectively (Table 1).nical isolates and their associated MICs against the second
No. of Isolates MIC (mg/L)
AMK KAN CAP
25 >40 >20 5.0
20 >40 >20 10
3 >40 >20 15
1 0.5 2.5 60.625
1 60.25 5.0 60.625
1 0.5 5.0 60.625
1 1.0 5.0 2.5
1 1.0 2.5 1.25
1 0.5 10 60.625
1 0.5 5.0 60.625
1 60.25 5.0 60.625
1 60.25 10 60.625
1 1.0 10 1.25
1 60.25 60.625 60.625
1 4.0 10 5.0
25 60.25 60.625 60.625
5 0.5 60.625 1.25
type.
at their respective break points, could contain a mutation in gene
372 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 5 ( 2 0 1 6 ) 3 7 0 –3 7 2The eis promoter mutations correlatedwith low-level AMK
and CAP resistance, and moderate-level KAN resistance.
Should be changed to
The eis promoter mutations correlated with low-level AMK
and CAP resistance, and low to moderate-level KAN
resistance.
(g) In Discussion;
The eis promoter mutations C-14T and G-10A corre-
sponded to low- or moderate-level resistance to KAN, with
KAN MICs generally ranging from 2.5 lg/mL to 10 lg/mL.Table 2 – Pyrosequencing results for 20 Mycobacterium tuberculo
No. of Isolates GenoType MTBDRsl assay DST
AMK
8 WT Susceptib
3 WT Susceptib
4 WT Susceptib
1 WT Resistant
4 rrs-MUT1 Resistant
Note: AMK = amikacin; CAP = capreomycin; DST = drug-susceptibility testThis should be changed to
The eis promoter mutations C-14T and G-10A corre-
sponded to low- or moderate-level resistance to KAN, with
KAN MICs ranging from 6 0.625 mg/L to 10 mg/L.
(h) Heading of the Table 2 i.e. Table 2 – Pyrosequencing
results for 20 Mycobacterium tuberculosis clinical isolates with
wild-type MTBDRsl assay results Should be Changed to
Table 2: Pyrosequencing results for 20Mycobacterium tuberculo-
sis clinical isolates with Genotype MTBDRsl assay results.sis clinical isolates with Genotype MTBDRsl assay results.
PSQ
KAN CAP
le Resistant Susceptible eis mutation
le Susceptible Susceptible eis mutation
le Susceptible Susceptible WT
Resistant Resistant WT
Resistant Resistant A1401G
ing; KAN = kanamycin; PSQ = pyrosequencing; WT = wild type.
